BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 29720731)

  • 1. Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents.
    Avet-Loiseau H; Facon T
    Leukemia; 2018 Jun; 32(6):1267-1276. PubMed ID: 29720731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
    Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Gagelmann N; Eikema DJ; Koster L; Caillot D; Pioltelli P; Lleonart JB; Reményi P; Blaise D; Schaap N; Trneny M; Passweg J; Porras RP; Cahn JY; Musso M; Poiré X; Fenk R; Itälä-Remes M; Pavone V; Fouillard L; Maertens J; Bron D; Pouli A; Schroyens W; Schönland S; Garderet L; Yakoub-Agha I; Kröger N
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2134-2142. PubMed ID: 31288095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
    Sonneveld P; Avet-Loiseau H; Lonial S; Usmani S; Siegel D; Anderson KC; Chng WJ; Moreau P; Attal M; Kyle RA; Caers J; Hillengass J; San Miguel J; van de Donk NW; Einsele H; Bladé J; Durie BG; Goldschmidt H; Mateos MV; Palumbo A; Orlowski R
    Blood; 2016 Jun; 127(24):2955-62. PubMed ID: 27002115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
    Dimopoulos MA; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Spencer A; Knop S; Bahlis NJ; Renner C; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel JF
    Haematologica; 2015 Oct; 100(10):1327-33. PubMed ID: 26250580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma with high-risk cytogenetics and its treatment approach.
    Hanamura I
    Int J Hematol; 2022 Jun; 115(6):762-777. PubMed ID: 35534749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
    Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
    Waheed S; Shaughnessy JD; van Rhee F; Alsayed Y; Nair B; Anaissie E; Szymonifka J; Hoering A; Crowley J; Barlogie B
    Cancer; 2011 Mar; 117(5):1001-9. PubMed ID: 20945320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
    Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
    Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.
    Moulopoulos LA; Dimopoulos MA; Kastritis E; Christoulas D; Gkotzamanidou M; Roussou M; Koureas A; Migkou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Gika D; Koutoulidis V; Terpos E
    Am J Hematol; 2012 Sep; 87(9):861-4. PubMed ID: 22641455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
    Königsberg R; Zojer N; Ackermann J; Krömer E; Kittler H; Fritz E; Kaufmann H; Nösslinger T; Riedl L; Gisslinger H; Jäger U; Simonitsch I; Heinz R; Ludwig H; Huber H; Drach J
    J Clin Oncol; 2000 Feb; 18(4):804-12. PubMed ID: 10673522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification in the era of novel therapies.
    San-Miguel J; Mateos MV; Gutierrez NC
    Cancer J; 2009; 15(6):457-64. PubMed ID: 20010164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
    Cejalvo MJ; de la Rubia J
    Future Oncol; 2015; 11(11):1643-58. PubMed ID: 25857329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies.
    Mina R; Bonello F; Petrucci MT; Liberati AM; Conticello C; Ballanti S; Musto P; Olivieri A; Benevolo G; Capra A; Gilestro M; Galieni P; Cavo M; Siniscalchi A; Palumbo A; Montefusco V; Gaidano G; Omedé P; Boccadoro M; Bringhen S
    Haematologica; 2021 Apr; 106(4):1079-1085. PubMed ID: 32107329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.
    Kaufman GP; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Dingli D; Hayman SR; Kapoor P; Lust JA; Russell S; Go RS; Hwa YL; Kyle RA; Rajkumar SV; Kumar SK
    Leukemia; 2016 Mar; 30(3):633-9. PubMed ID: 26487275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
    Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
    Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic stratification of multiple myeloma treated with novel agents.
    Jiang A; Reece D; Chang H
    Leuk Lymphoma; 2012 Feb; 53(2):202-7. PubMed ID: 21823830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment strategy for untreated transplantation-ineligible multiple myeloma patients].
    Suzuki T
    Rinsho Ketsueki; 2020; 61(9):1297-1305. PubMed ID: 33162529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.